Structure Therapeutics, Inc. · NASDAQ:GPCR
Structure Therapeutics — Investor Presentation (June 2026)
21 slides from Structure Therapeutics's investor presentation, June 2026
Slide 1: Medicine is our platform. Accessibility is our cure.
Medicine is our platform. Accessibility is our cure. Corporate Presentation June 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking s
Slide 3: Our Mission
Our Mission Our Mission Making medicines more accessible to all 34
Slide 4: Overview and Growth Opportunity
Overview and Growth Opportunity Aleniglipron was designed to achieve the efficacy of an injectable with the convenience of an oral pill and has the potential to scale to meet the needs of the global obesity patient population GLP-1 Receptor ORAL SMALL MOLECULE >1 billion worldwide 1 Agonist ALENIGLI
Slide 5: Launch of Oral Therapies in 2026 has Demonstrated Unprecedented Growth and Unmet Need and Demand
Launch of Oral Therapies in 2026 has Demonstrated Unprecedented Growth and Unmet Need and Demand >1.2M patients on therapy in Q1 2026; Weekly Oral TRx Share far exceeding the US obesity GLP-1 market1 Zepbound launch Key insights 16% 14% Oral Wegovy® has been the fastest GLP-1 launch to-date2: >1.2M
Slide 6: Structure is Uniquely Positioned to Develop Multiple Oral Obesity Treatments
Structure is Uniquely Positioned to Develop Multiple Oral Obesity Treatments That Could Scale to Meet the Global Unmet Need GLP-1 Receptor Amylin Receptor GLP-1 + Amylin Other Combinations GLP-1R + Amylin + GIPR GIPR GLP-1R + GLP-1R + GCGR GIPR + GCGR Aleniglipron ACCG-2671 Fixed Dose Combination •
Slide 7: 2026: A Transformational Year as Aleniglipron Advances into Phase 3
2026: A Transformational Year as Aleniglipron Advances into Phase 3 Discovery and Development of a Strong and Broad Portfolio of Obesity related Oral Assets IND- Program Molecule(s) Study / Focus Discovery Lead Opt enabling/ Phase 1 Phase 2 Phase 3 DC End of Pivotal Phase 3 initiation Phase 3 Regist
Slide 8: Aleniglipron
Aleniglipron Selective GLP-1 Receptor Agonist Oral Small Molecule 8
Slide 9: Aleniglipron Phase 2b Demonstrates Potential Best-in-Class Profile
Aleniglipron Phase 2b Demonstrates Potential Best-in-Class Profile ACCESS ACCESS OLE ACCESS II 11.3% 16.2% 16.3% Body weight loss: at 36 weeks at 56 weeks at 44 weeks 120 mg 120 mg 180 mg AE-related 10.4% in ACCESS over 36 weeks 3.7% in ACCESS II after re-randomization at 28 weeks discontinuations:
Slide 10: Aleniglipron ACCESS and ACCESS II Weight Loss Summary
Aleniglipron ACCESS and ACCESS II Weight Loss Summary* Up to 16.3% weight loss and no evidence of plateauing Published: June 5, 2026** DOI: 10.1038/s41591-026-04476-6 *All data shown as placebo-adjusted primary efficacy estimand. ** https://www.nature.com/articles/s41591-026-04476-6 10
Slide 11: Participant Journey Responding to GI AEs on 120 mg dose of aleniglipron
Participant Journey Responding Dosage, 5 mg 15 mg 90 mg 120 mg 30 mg 45 mg to GI AEs on mg 120 mg dose of aleniglipron Published: June 5, 2026 Participants who completed DOI: 10.1038/s41591-026-04476-6 treatment (N=30, 47%) • Majority participants followed titration as scheduled • Dose interruptions
Slide 12: Aleniglipron Participant Journey to Chronic Weight Management
Aleniglipron Participant Journey to Chronic Weight Management Key Questions 1 What is the top dose? Potential best-in-class efficacy – 16.3% weight loss at 180 mg dose Does weight loss and ACCESS OLE 2 continue beyond 36 weeks? No evidence of plateauing at 44 weeks (ACCESS II) and 56 weeks (ACCESS O
Slide 13: Ongoing Aleniglipron Clinical Studies
Ongoing Aleniglipron Clinical Studies Clinical Study Rationale and Opportunity Data Readout • ACCESS placebo participants continue into OLE with 2.5 ACCESS mg starting dose to 180 mg over 36 weeks Q3 2026 OLE • ACCESS treated participants continue into OLE for up to 72 weeks up to 180 mg Body • 2.5
Slide 14: Aleniglipron Phase 3 Expected to Initiate in Q3 2026
Aleniglipron Phase 3 Expected to Initiate in Q3 2026 Phase 3 Design Elements 2.5 mg • Positive End-of-Phase 2 Starting Dose meeting in May 2026 • Alignment reached on key design elements Aleniglipron 4-week (3 Target Doses) Titration Steps required for Phase 3 registrational program Placebo • Phase
Slide 15: ACCG-2671
ACCG-2671 Amylin Receptor Agonist Oral Small Molecule
Slide 16: ACCG-2671 Preclinical Profile
ACCG-2671 Preclinical Profile ACCG-2671 Profile Oral Small Molecule Injectable Peptide ACCG-2671 Cagrilintide • Dual Amylin and Calcitonin Receptor Agonist (DACRA) Ki hAMY3R <5 nM 3.5 nM In vitro • Nanomolar in vitro binding affinity to amylin affinity and calcitonin receptors Ki hCTR <5 nM 6.8 nM •
Slide 17: ACCG-2671 Phase 1 SAD Study Ongoing
ACCG-2671 Phase 1 SAD Study Ongoing • Evaluate the safety, tolerability, pharmacokinetics (PK), and food-effect of single ascending doses (SAD) of ACCG-2671 in healthy adult participants • Phase 1 data and move into 12 week MAD study on track for Q3 2026 Part 1 (n=40) Part 2 (n=12) Phase 1 Single As
Slide 18: ACCG-2671 and Combination Proof-of-Concept Study
ACCG-2671 and Combination Proof-of-Concept Study • ACCG-2671 demonstrated significant dose-dependent weight loss in obese non-human primates (NHPs) • Long half-life (t1/2 > 60 hr) in NHPs • Combination ACCG-2671 and aleniglipron resulted in −12.3% body weight loss in obese NHPs Vehicle 10 10 ACCG-26
Slide 19: Amylin + GLP-1 Receptor Combination Opportunity
Amylin + GLP-1 Receptor Combination Opportunity GLP-1 + Amylin Fixed Dose Combination • GLP-1R + Amylin Small Molecule Combination Proof of Concept achieved in obese NHPs • Combination clinical study initiation in Q4 2026 19
Slide 20: Strong Momentum with Multiple Potential Catalysts 2026 - 2028
Strong Momentum with Multiple Potential Catalysts 2026 - 2028 ~$1.5B in cash1 expected to fund Aleniglipron Phase 3 program through 2028 Anticipated Milestones Program 1H 2026 2H 2026 2027 2028 Phase 3 Data ACCESS II Data Chronic Weight Management ACCESS OLE Interim ACCESS OLE Data Aleniglipro
Slide 21: Our Mission
Our Mission Our Mission Making medicines more accessible to all NASDAQ: GPCR ir@structuretx.com www.structuretx.com 214
Structure Therapeutics — Investor Presentation (June 2026) on 6ix